Table 2.
Univariate analysis of variables with respect to survival outcomes
| Variable | DFS |
OS |
||
|---|---|---|---|---|
| HR (95 % CI) | HR (95 % CI) | p | ||
| Race | 0.21 | 0.38 | ||
| African American | 0.78 (0.53–1.15) | 1.19 (0.81–1.76) | ||
| Caucasian | Reference group | Reference group | ||
| Age (per 1 yr increase) | 1.00 (0.99–1.01) | 0.64 | 1.01 (1.00–1.03) | 0.07 |
| Chemotherapy for stage I–III disease | <0.001 | <0.001 | ||
| pCR, neoadjuvant chemotherapy | Reference group | Reference group | ||
| Non-pCR, neoadjuvant chemotherapy | 4.01 (1.45–11.12) | 0.008 | 5.61 (1.35–23.26) | 0.02 |
| Adjuvant chemotherapy alone | 1.68 (0.61–4.63) | 0.31 | 1.87 (0.45–7.80) | 0.39 |
| Menopausal statusa | 0.32 | 0.90 | ||
| Premenopausal | 1.20 (0.84–1.70) | 1.03 (0.69–1.54) | ||
| Postmenopausal | Reference group | Reference group | ||
| Pathological stage | <0.001 | <0.001 | ||
| pCR | Reference group | Reference group | ||
| I | 1.56 (0.55–4.39) | 0.40 | 2.64 (0.63–11.2) | 0.19 |
| IIA | 1.65 (0.58–4.66) | 0.34 | 1.52 (0.35–6.69) | 0.58 |
| IIB | 3.30 (1.14–9.54) | 0.03 | 3.95 (0.91–17.2) | 0.07 |
| III | 4.89 (1.76–13.6) | 0.002 | 6.91 (1.66–28.7) | 0.01 |
| IV | Not included | 44.1 (10.3–190.0) | <0.001 | |
| Grade | 0.13 | 0.75 | ||
| 3 | 1.50 (0.89–2.55) | 1.09 (0.63–1.88) | ||
| 1 and 2 | Reference group | Reference group | ||
a
Not considered in the multivariate analysis due to its high correlation with age